DexCom, Inc. announced the its new device-ONE Continuous Glucose Monitoring System, is slated for release in United Kingdom in this May. In the UK, Dexcom ONE is estimated to be a more affordable and accessible real-time CGM (rt-CGM) system for people with diabetes.
Novo Nordisk A/S announced that Ozempic 2.0 mg has been approved by the US Food and Drug Administration (FDA). Ozempic has now been approved for treating type 2 diabetes in adults at doses of 0.5 mg, 1.0 mg, and 2.0 mg in the United States.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 427
Published Date: Feb 13, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Worldwide rising incidences of chronic diseases, and growing improvement in glycemia in higher risk patients with the use of flash glucose monitoring, are some major factors driving the growth of the market.
The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.
Overloaded data issue with flash glucose monitoring, skin irritation caused by flash glucose monitoring systems, and lack of sufficient reimbursement for flash glucose monitoring systems are estimated to hamper the market growth.
The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
The major players in the market are Novo Nordisk A/S, DexCom, Inc., GlySens Incorporated, Medtronic plc, Insulet Corporation, Ypsomed Holding AG, F. Hoffmann-La Roche Ltd, Abbott Laboratories, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by modality, application, technology, end-user, and by region.
The hospitals segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.